Biofilms—structured communities of microbes encased in a self-produced matrix of proteins, polysaccharides, and extracellular DNA—are among the most stubborn threats in modern medicine. An estimated 65 to 80 percent of all infectious diseases are linked to these slimy fortresses, which include chronic wounds, lung infections in cystic fibrosis patients, and device-associated illnesses. The reason they are so difficult to treat lies in a sobering statistic: bacteria living inside biofilms can tolerate antibiotic concentrations up to 1,000-fold higher than their free-swimming planktonic counterparts. Now, a comprehensive review published in MicrobiologyOpen examines a surprising candidate for dismantling these microbial strongholds: carbon quantum dots, fluorescent nanoparticles smaller than ten nanometers that can be manufactured from sources as mundane as fruit juice, honey, garlic, and even discarded intravenous bags.
Carbon dots have quietly attracted attention over the past decade for their unusual combination of properties. They are photochemically stable, biocompatible, low in toxicity, and fluorescent, which has already made them useful in cellular imaging, biosensing, and drug delivery. But what makes them especially interesting in the antibiofilm arena is their synthetic flexibility. Researchers can choose precursors and synthesis methods that deliberately install specific surface functionalities—amines for a positive charge, carboxylic acids for a negative charge, or hydrophobic domains—each of which governs how the dots interact with the complex architecture of a biofilm and the cells hidden within it. In other words, the recipe determines the weapon.
The review, written by a team led by Hadeer M. Bedair and Tamer M. Samir, categorizes synthesis strategies into top-down and bottom-up approaches, with the latter dominating current research. Hydrothermal, solvothermal, microwave-assisted, pyrolysis, and thermal decomposition methods convert small organic molecules or biomass into nanosized carbon cores through dehydration, polymerization, aromatization, and carbonization. Microwave-assisted synthesis has emerged as a standout because it heats the reaction volumetrically through dielectric heating, shrinking reaction times from hours to minutes while promoting homogeneous nucleation and often improving fluorescence and yield. Still, the method is not without drawbacks: product quality depends heavily on microwave power, reaction time, precursor composition, and solvent properties, and scale-up remains challenging because microwave penetration depth decreases as reaction volume grows—a limitation that pushes researchers toward dedicated laboratory reactors rather than domestic ovens.
When it comes to Gram-positive bacteria, the review finds that cationic design has been the dominant strategy. The cell walls of bacteria such as Staphylococcus aureus carry a net negative charge, courtesy of teichoic acids and phospholipid membranes, so positively charged dots bind electrostatically and tear membranes apart. The comparative data reveal striking differences. Quaternized carbon dots achieved complete prevention of S. aureus biofilm at 1,000 micrograms per milliliter, while polyethyleneimine–citric acid dots required 1,500 micrograms per milliliter. In contrast, spermidine-capped carbon dots achieved 81.34 percent inhibition at just 16 micrograms per milliliter, and guanidinium-based dots reduced methicillin-resistant S. aureus biofilm to near-zero levels at 20 micrograms per milliliter. The guanidinium group, capable of forming bidentate hydrogen bonds with negatively charged cell-surface components in addition to electrostatic attraction, appears to be a particularly potent motif. The message is clear: the molecular architecture of the cationic moiety matters as much as the charge itself.
Beyond brute-force electrostatics, the review highlights increasingly sophisticated smart designs. Folic acid-derived carbon dots exploit folate receptors overexpressed on many bacterial species to target infection sites, disrupting 82 percent of mature S. aureus biofilms at 1,000 micrograms per milliliter. A pH-responsive dissociable nanosystem remains inert during transit but disassembles within the acidic microenvironment of a growing biofilm, releasing both a biocidal cationic polymer and l-lysine-derived dot cores that generate intracellular reactive oxygen species, degrading the extracellular matrix and killing embedded bacteria. Perhaps most striking is a conversion strategy in which the antibiotic gentamicin sulfate was directly calcined into carbon dots, yielding a material that retained the parent drug’s active structure while gaining a positively charged surface and reactive oxygen species generation. The result: more than 99 percent destruction of S. aureus biofilms at just 80 micrograms per milliliter, with low observed drug resistance—a compelling route to repurposing existing antibiotics into multifunctional nanomaterials.
Gram-negative pathogens present a far harder problem. Their outer membrane, an asymmetric bilayer rich in lipopolysaccharide, functions as a formidable permeability barrier that blunts the electrostatic interactions so effective against Gram-positive cells. Nitrogen-doped dots that fully inhibited Bacillus subtilis biofilm at 25 milligrams per milliliter required the same high concentration to inhibit Escherichia coli, a disparity the authors attributed to the thicker lipopolysaccharide layer. Effective concentrations against Gram-negative targets in the reviewed literature span more than four orders of magnitude, from 4 micrograms per milliliter to 25,000. The most potent systems share a common feature: multiple synergistic mechanisms rather than electrostatics alone. A cobalt-nickel ferrite/silica/titania/carbon-dot nanocomposite combining photocatalysis with magnetic properties inhibited 93.92 percent of E. coli biofilm at just 15 micrograms per milliliter. An iron and nitrogen co-doped nanozyme with peroxidase-like activity achieved 73.2 percent inhibition of Hafnia alvei biofilm at 4 micrograms per milliliter by converting hydrogen peroxide into toxic hydroxyl radicals—and, in a practical demonstration, extended the shelf life of salmon by three to six days. Red-emissive dots activated by light achieved 85 percent inhibition of multidrug-resistant Acinetobacter baumannii biofilm at 150 micrograms per milliliter through photodynamic generation of reactive oxygen species, an approach particularly suited to wound and device infections where light can be applied externally.
Fungal biofilms, especially those formed by Candida species, represent a distinct clinical challenge because fungal cells are eukaryotic, making selective toxicity substantially harder to achieve. The review notes that research here remains scarce but promising. Simple dots made from Citrus limetta fruit juice achieved a modest 40 percent reduction of Candida albicans biofilm at 75 micrograms per milliliter, likely through interference with quorum sensing and initial adhesion. More sophisticated designs fared better: guanidine-functionalized red-emissive dots conjugated with amphotericin B significantly reduced C. albicans biofilm at 100 micrograms per milliliter while preserving the integrity of reconstituted human oral epithelial tissue—a crucial demonstration of selective toxicity. The magnetic-photocatalytic nanocomposite inhibited 92.35 percent of Candida tropicalis biofilm at 15 micrograms per milliliter, though its lower activity against C. albicans underscores how sharply antifungal susceptibility varies even within a single genus. In another innovative approach, red-emitting dots embedded in poly-l-lactic acid scaffolds convert near-infrared light into localized heat, achieving 60 percent inhibition of clinical Candida parapsilosis biofilms—a physical mechanism unlikely to induce resistance and readily adaptable to self-sterilizing medical devices.
Mechanistically, the review argues that no single mode of action explains carbon dot antibiofilm activity; rather, the most effective systems combine several. Electrostatic binding initiates contact with anionic bacterial surfaces and matrix components. The ultrasmall size of the dots—typically below ten nanometers—allows them to diffuse through the water channels of the extracellular matrix that exclude most conventional antibiotics, reaching persister cells in the deepest layers. Once internalized, many dots trigger intracellular reactive oxygen species, damaging proteins, lipids, and DNA while simultaneously degrading the matrix polysaccharides and extracellular DNA that hold the biofilm together. Intriguingly, some dots work without killing cells at all. Curcumin-derived dots downregulated adhesion and biofilm maturation genes in Enterococcus faecium, while tinidazole-functionalized dots suppressed fimbriae and protease genes in Porphyromonas gingivalis. Bacteria-derived dots inhibited E. coli biofilm formation without affecting planktonic growth at all, pointing to specific interference with regulatory pathways such as sulfur metabolism or cyclic di-GMP signaling. This disarming strategy, which disrupts the regulatory networks governing biofilm formation rather than the cells themselves, may exert less selective pressure for resistance—one of the most tantalizing implications of the entire field.
The authors are candid about the hurdles between laboratory promise and clinical reality. Effective concentrations vary enormously across studies, partly because testing protocols are not standardized, making direct comparisons difficult. The molecular events governing how dots traverse the Gram-negative outer membrane, and how they achieve selective toxicity against microbes without harming mammalian cells, remain poorly understood. Almost all published results come from in vitro experiments; long-term biocompatibility, biodistribution, pharmacokinetics, immunogenicity, and environmental safety in living organisms have barely been examined. Large-scale production, batch-to-batch consistency, storage stability, and regulatory approval remain unsolved. The review calls for standardized synthesis and characterization protocols, systematic structure–activity studies, testing against clinically relevant multispecies biofilms and drug-resistant isolates in realistic infection models, and eventually rigorous preclinical and clinical trials. If those challenges are met—potentially aided by artificial intelligence-assisted nanomaterial design and green synthesis—the authors believe carbon quantum dots could evolve from experimental curiosities into safe, effective platforms for the prevention, diagnosis, and treatment of biofilm-associated infections, offering a genuinely new weapon against one of medicine’s most persistent enemies.
Subject of Research: The antibiofilm activity of carbon quantum dots against bacteria and fungi
Article Title: Insights Into the Antibiofilm Activity of Carbon Quantum Dots Against a Panel of Different Microorganisms: A Review
Article References: Bedair, H. M., Hamed, M., Shoun, A. A., Mansour, F. R., Obaydo, R. H., & Samir, T. M. (2026). Insights Into the Antibiofilm Activity of Carbon Quantum Dots Against a Panel of Different Microorganisms: A Review. MicrobiologyOpen, 15(5), Article e70411. https://doi.org/10.1002/mbo3.70411
Image Credits: AI Generated
DOI: 10.1002/mbo3.70411
Keywords: carbon quantum dots, biofilms, antimicrobial resistance, nanomaterials, MRSA, reactive oxygen species, quorum sensing, Gram-negative bacteria, Candida, nanotechnology, antibiofilm therapy, photodynamic therapy
Cite Scienmag News
Katie Riggs. (September 22, 2026). Carbon Quantum Dots Show Promise Against Drug-Resistant Biofilms. Scienmag. https://scienmag.com/carbon-quantum-dots-show-promise-against-drug-resistant-biofilms/
Katie Riggs. "Carbon Quantum Dots Show Promise Against Drug-Resistant Biofilms." Scienmag, 22 September 2026, https://scienmag.com/carbon-quantum-dots-show-promise-against-drug-resistant-biofilms/. Accessed 22 September 2026.
Katie Riggs. "Carbon Quantum Dots Show Promise Against Drug-Resistant Biofilms." Scienmag. September 22, 2026. https://scienmag.com/carbon-quantum-dots-show-promise-against-drug-resistant-biofilms/

